Reprogramming macrophage by targeting VEGF and CD40 potentiates OX40 immunotherapy
- 18 January 2024
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 698, 149546
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (32171468, 32271529, 82104092, 82273843, 82373898)
- Shenzhen Municipal Fundamental Research Program (JCYJ20210324121814039)
This publication has 20 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Rationale for anti-OX40 cancer immunotherapyEuropean Journal of Cancer, 2016
- Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculatureMatrix Biology, 2015
- Molecular signatures of antibody responses derived from a systems biology study of five human vaccinesNature Immunology, 2013
- Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC)Cancer Biology & Therapy, 2011
- CD40 Ligation Activates Murine Macrophages via an IFN-γ-Dependent Mechanism Resulting in Tumor Cell Destruction In VitroThe Journal of Immunology, 2005
- Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITRBlood, 2005
- Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell ResponsesThe Journal of Immunology, 1998
- Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.Journal of Experimental Medicine, 1994
- Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions.The Journal of Immunology, 1993